Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL

Autor: A. Schrader, G. Crispatzu, S. Oberbeck, P. Mayer, S. Pützer, J. von Jan, E. Vasyutina, K. Warner, N. Weit, N. Pflug, T. Braun, E. I. Andersson, B. Yadav, A. Riabinska, B. Maurer, M. S. Ventura Ferreira, F. Beier, J. Altmüller, M. Lanasa, C. D. Herling, T. Haferlach, S. Stilgenbauer, G. Hopfinger, M. Peifer, T. H. Brümmendorf, P. Nürnberg, K. S. J. Elenitoba-Johnson, S. Zha, M. Hallek, R. Moriggl, H. C. Reinhardt, M.-H. Stern, S. Mustjoki, S. Newrzela, P. Frommolt, M. Herling

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-22 (2018)

T-cell prolymphocytic leukemia (T-PLL) is a rare malignancy with a poor prognosis. Here, the authors investigate the genomic landscape, gene expression profiles and functional mechanisms in 111 patients, highlighting TCL1 overexpression and ATM aberr

Externí odkaz: https://doaj.org/article/27f303840c0c4d6e8ca4ef99b0371076

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Autor: Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman

Publikováno v: Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c34416fb3adf2a299c05113cf960a2c
https://doi.org/10.1016/s1470-2045(20)30324-7

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Autor: Ana Tablante Nunes, Bradley J. Monk, Michelle Marcovitz, Mary Li, Jyoti Mayadev, M. Lanasa

Publikováno v: International Journal of Gynecological Cancer

BackgroundConcurrent chemoradiotherapy is the standard of care for locally advanced cervical cancer. Concurrent chemoradiotherapy with programmed blockade of the cell death-1/programmed cell death-ligand 1 pathway may promote a more immunogenic envir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5a15ca11b79634fa7e73b1a9db3473
https://pubmed.ncbi.nlm.nih.gov/32447296

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Autor: Sook-Hee Hong, Ricardo H. Alvarez, Young-Ae Park, Susana Banerjee, A. Lortholary, M. Ferguson, C. Gresty, Susan M. Domchek, Yvette Drew, P. Herbolsheimer, Helen K. Angell, Bella Kaufman, Patricia Roxburgh, M. Lanasa, K. Meyer, Stefan Zimmermann, M.J.A. de Jonge, V Rocher Ros

Publikováno v: Annals of Oncology. 30:v485-v486

Background Olaparib (Lynparza®) is a poly(ADP-ribose) polymerase (PARP) inhibitor approved as maintenance treatment of PSR OC. MEDIOLA assessed olaparib in combination with the anti-programmed cell death ligand1 antibody, durvalumab, in germline BRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7439d38946fb0ab591647cb3adaa6866
https://doi.org/10.1093/annonc/mdz253.016

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Autor: S.-A. Im, J.-P. Delord, Antoine Italiano, Benoit You, Sophie Postel-Vinay, P. Herbolsheimer, Helen K. Angell, Young-Ae Park, S. Waqar, Jérôme Alexandre, Bella Kaufman, Ding Wang, Zhongwu Lai, M. Lanasa, C. Gresty, L Opincar, Susan M. Domchek, Matthew G Krebs, S Bastian

Publikováno v: Annals of Oncology. 30:v477

Background O (olaparib, Lynparza®) is approved for gBRCAm HER2(-) MBC based on the OlympiAD study. O-induced DNA damage may increase tumor antigen release, activate cGAS/STING, attract tumor-infiltrating lymphocytes and upregulate programmed cell de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2a5acf191e123bfbbe3bce0742af80a
https://doi.org/10.1093/annonc/mdz253.017